Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Sanofi CEO Paul Hudson stated: “We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already ...

Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

L’Oréal remains an important shareholder of Sanofi and is fully supportive of the company’s value creation strategy,” said ...

Sanofi (SNYNF, SNY) reported fourth quarter net income from continuing operations of 880 million euros compared to a loss of 119 ...

Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...

PARIS — L’Oréal has agreed to sell about 29.6 million Sanofi shares to Sanofi for approximately 3 billion euros.